Digital Pathology Services

With innovative High-multiplex Imaging technologies (Learn more about our Hyperion platform) combined with advanced software analysis including AI and Deep learning tools, we measure and quantify a large number of biomarkers in Drug Discovery, Translational research or Clinical research programs.  Recent innovation in this spatial bio-analysis space allows to anticipate or predict patient response to drug treatment by measuring at protein, RNA and metabolism. The Biomarker services can also be tied-up to drug biodistribution studies to bring better drug pharmacology impact (discover drug biodistribution platform).

Drug Discovery and Preclinical Services

ImaBiotech developed an expertise in Image analysis, batch effect and qualitative and quantitative measurement of biomarker distribution in drug discovery (learn more about our proprietary software analysis) to support multiple applications:

    • Target Validation:

We can measure target expression in tissues and detect changes in response to drug treatment.  We have experience with Core Needle Biopsies,  resected tumor tissues, tissue microarrays (TMAs), that allow screening of tissue types for target expression. Use us for analysis of multiplex images to identify accurately which cells types express your target.

    • Validation of In vivo Models and Readouts:

Image analysis can be used to quantify biomarker and/or target expression in models in vivo.  Our image analysis services can be used to quantify mechanistic responses to drug treatment such as proliferation, apoptosis, angiogenesis and inflammatory cell infiltrate etc. We have extensive expertise in quantitative analysis of Xenograft study read-outs including evaluation of necrosis / viable content and a wide range of intercellular markers and mechanistic processes; leveraging in vivo tumor models to discover new oncology targets and confirm efficacy of putative drug molecules.

    • Biomarker Identification:

We have extensive expertise in quantitative analysis of Xenograft study read-outs including evaluation of necrosis / viable content and a wide range of intercellular markers and mechanistic processes; leveraging in vivo tumor models to discover new oncology targets and confirm efficacy of putative drug molecules.

Hyperion multiplex imaging

Translation research

    • Target Expression:

Image analysis can be used to quantify and localise target expression in the absence and presence of drug treatment and across  healthy and diseased human tissue. We have experience with tissue microarrays (TMAs),  that allow screening of tissue types for target expression.

    • Biomarker Evaluation:

Biomarker IHC staining can be quantified on a cell by cell basis in pre-clinical model tissues for determination of the best biomarkers to evaluate in clinical trial tissue samples. Biomarkers can demonstrate evidence of early pharmacodynamic readouts or toxicity profiles in tissues to better guide dose setting in later stage trials.

    • Patient Stratification:

Changes in specific mechanistic readouts and/or intercellular signalling proteins can predict drug response in specific patient populations. We can quantify changes in marker expression across whole tissues or within specific regions of interest to provide data guiding which disease types to target for therapy.

Clinical Services

    • Drug Efficacy and patient response

With high-multiplex imaging, we include biomarkers of phenotypes, drug target markers and biomarkers of the cell signaling pathways. We quantify the impact of the drug to cell microenvironment, reshaping of the environment and score the activation or inhibition of pathway of interest.

    • Patient Stratification:

Quantification of specific tissue markers, mechanistic readouts or intercellular signaling proteins can predict drug response or disease status within specific patient populations. Our services provide detailed quantification of changes in marker expression across whole tissues or within specific regions of interest to better guide choice of drug dose or clinical population for trial inclusion.

Expertise in Image Analysis

We developed proprietary software, including Deep and machine learning as well as quality controls in a GLP environment in the analysis process to guarantee accuracy and precision with transparency to our clients.

    • Quality control points at image QC, tissue annotation and algorithm development stages.
    • Maximized accuracy in cell detection and segmentation as a critical step for digital pathology analysis
    • Validation steps to ensure algorithm accuracy

Cell segmentation

Resources

MediaTitle
Application NoteFollowing toxicity and efficacy markers in skin substructures using Mass Spectrometry Imaging (MSI)
PublicationAutomated Morphological and Morphometric Analysis of Mass Spectrometry Imaging Data: Application to Biomarker Discovery
Brochure Digital Pathology Services
Application Note Spatial quantification of biomarkers within target tissues with image analysis platform
White Paper An Image-based data-driven analysis of metabolite clusters architecture in heterogeneous colorectal cancer tissues

Request a quote